Bromfenac Sodium Polymorph Crystallization Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of information on the crystal structure and polymorphs of bromfenac sodium, which affects its solubility, stability, and bioavailability, as well as the development of reliable methods for converting between its crystalline forms.
Innovation Solution
Three well-defined and reproducible crystalline forms of bromfenac sodium (Forms I, II, and III) are developed, along with scalable methods for interconverting them, using solvent mixtures and anti-solvents to achieve high purity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If bromfenac sodium is crystallized from conventional solvents, then the crystal structure and polymorphs are not well-defined, but the solubility, stability, and bioavailability are significantly affected
Solution Approach 1:
The patent applies parameter changes by systematically varying solvent composition (using mixtures of water, organic solvents like ethanol or isopropanol, and their ratios), temperature parameters (crystallization temperature ranges from -20°C to 25°C), and pH conditions to obtain well-defined crystal structures with specific polymorphic forms, thereby resolving both the precision of crystal definition and the reliability of solubility and stability
Solution Approach 2:
The patent uses intermediary substances including specific solvents (water, ethanol, isopropanol), anti-solvents (acetone, ethyl acetate, diethyl ether), and additives (citric acid, sodium citrate, hydrochloric acid, sodium hydroxide) as mediators to control the crystallization process, enabling the formation of well-defined polymorphs with improved solubility, stability, and bioavailability characteristics
2Reliability
If multiple polymorphs are produced, then solubility and bioavailability can be optimized, but the process complexity increases
Solution Approach 1:
The patent segments the crystallization process into distinct pathways for producing different polymorphs (Form I, Form II, Form III, Form IV, Form V) based on specific solvent systems and conditions. Each polymorph has a defined preparation method using segmented approaches: Form I uses water-organic solvent mixtures at controlled temperatures, Form II uses anti-solvent addition, Form III uses specific pH conditions, allowing selective production without requiring complex multi-step processes
Solution Approach 2:
The patent applies inversion by converting between polymorphs through reverse processes: hydrating anhydrous forms to obtain hydrated forms, or dehydrating hydrated forms to obtain anhydrous forms. This allows flexibility in producing the desired polymorph with optimal solubility and bioavailability by reversing the crystallization conditions or using conversion processes rather than direct synthesis
3Manufacturing precision
If high purity polymorphs are obtained, then pharmaceutical quality is improved, but the manufacturing cost and time increase
Solution Approach 1:
The patent applies preliminary action by pre-selecting optimal solvent systems and crystallization conditions for each polymorph form before actual production. The defined protocols for each polymorph (Form I through Form V) include pre-determined solvent ratios, temperature profiles, and pH conditions that directly yield high purity products with minimal need for additional purification steps, thereby maintaining manufacturing efficiency
Solution Approach 2:
The patent employs self-service through self-assembly crystallization processes where the polymorphs form with inherent high purity through controlled crystallization conditions. The use of anti-solvents and pH adjustment allows the crystals to self-purify during the crystallization process, with impurities remaining in the mother liquor, eliminating the need for complex post-crystallization purification steps and maintaining productivity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The methods enable the production of bromfenac sodium polymorphs with improved stability, solubility, and bioavailability, suitable for pharmaceutical formulations, particularly for ophthalmic use.
Implementation Method 1
crystallizing or recrystallizing bromfenac sodium from a solvent mixture comprising water, at least one dialkoxyalkane, and at least one anti-solvent
Implementation Method 2
crystallizing or recrystallizing bromfenac sodium from a solvent mixture comprising water, at least one dialkoxyalkane, and at least one anti-solvent
Implementation Method 3
Bromfenac sodium Form II is a hydrate of bromfenac sodium containing less than 1.5 moles of water per mole of bromfenac sodium
Implementation Method 4
Bromfenac sodium Form III is a non-hydrated polymorph of bromfenac sodium
Data Source
AI summary
Different polymorphs of bromfenac sodium may be prepared and interconverted using crystallization/recrystallization, drying and/or hydration techniques.